Computational design of potent, broadly neutralizing anti-Nipah virus and Hendra virus miniproteins
Preprint
Abstract
The prototype members of the genus Henipavirus, Nipah virus (NiV) and Hendra virus (HeV), cause recurrent zoonotic spillovers with case fatality rates ranging from 40-90% in humans. Currently, there are no approved vaccines or therapeutics for use in humans. Neutralizing antibodies targeting the NiV/HeV F-or G-glycoproteins protect animals from lethal challenge and are a main correlate of protection. However, antibody-based formulations are expensive, typically requiring hospital admission for administration and cold-chain for storage and transportation. To address the lack of shelf-stable clinical countermeasures, we computationally designed thermostable miniproteins that cross-react with subnanomolar affinities with both NiV and HeV F and G glycoproteins and inhibit viral entry in vitro with potencies comparable to lead antibodies. Oligomerized forms of these miniproteins have enhanced potency relative to their monomeric building blocks and increase the barrier for emergence of escape mutants, establishing them as promising preclinical candidates against these deadly viruses.Keywords
Funding Information
- Burroughs Wellcome Fund
- National Institutes of Health (AI181930)
- National Institutes of Health (AI142764)
This publication has 62 references indexed in Scilit:
- Designed miniproteins potently inhibit and protect against MERS-CoVCell Reports, 2025
- Functional and antigenic landscape of the Nipah virus receptor-binding proteinCell, 2025
- A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spikeCell, 2023
- High-throughput identification of autoantibodies that target the human exoproteomeCell Reports Methods, 2022
- Cooperativity mediated by rationally selected combinations of human monoclonal antibodies targeting the henipavirus receptor binding proteinCell Reports, 2021
- Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and diseaseCell Host & Microbe, 2021
- Potent Henipavirus Neutralization by Antibodies Recognizing Diverse Sites on Hendra and Nipah Virus Receptor Binding ProteinCell, 2020
- Epidemiology of Henipavirus Disease in Humans2012
- UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004
- Optimal Determination of Particle Orientation, Absolute Hand, and Contrast Loss in Single-particle Electron CryomicroscopyJournal of Molecular Biology, 2003